Tandem Diabetes Care Inc. (TNDM)
Tandem Diabetes Valuation: Is 1.1x Sales a Buy?
TNDM trades near 1.1x forward sales as it shifts to pharmacy pay-as-you-go and expands Europe, with a $21 target tied to 1.3x sales.
TNDM Stock: What to Know About Tandem's 2026 Reset
Tandem Diabetes' Q1 beat, fatter margins and positive cash flow fuel its 2026 reset as it shifts more U.S. pump starts to pay-as-you-go pharmacy.
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up
Tandem Diabetes beats Q1 revenue and earnings estimates as gross margin expands, but shares decline 23.6% after the results announcement.
Tandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tandem Diabetes Care (TNDM) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Tandem Diabetes Care (TNDM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Tandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call Transcript
Tandem Diabetes Care Q1 Earnings Call Highlights
Tandem Diabetes Care NASDAQ: TNDM reported record first-quarter pump shipments and sales for 2026, while reaffirming its full-year outlook as the diabetes technology company advances a shift toward pharmacy-channel reimbursement, expands direct international operations and prepares several product launches.
Compared to Estimates, Tandem Diabetes Care (TNDM) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Strength Seen in Tandem Diabetes Care (TNDM): Can Its 9.1% Jump Turn into More Strength?
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now
New pump launches, CGM integrations and strong solvency support Tandem Diabetes' growth outlook, though intense competition and macro headwinds remain risks.
Tandem Diabetes Care, Inc. (TNDM) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
Tandem Diabetes Care, Inc. (TNDM) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
Tandem Diabetes Care: Strong Q4 Execution Amid A PayGo Transition
Tandem Diabetes Care, Inc. delivered strong Q4 '25 results, with revenue and gross margin beats driving a 32% stock surge. TNDM's shift to a pay-as-you-go model will temporarily compress reported revenue but should enable smoother, recurring income and improved long-term economics.
